Investigating how a specific enzyme affects fungal infections in immunocompromised patients
Official title: Sphingosine kinase and cryptococcal granuloma
Funded at State University New York Stony Brook · NIH-11126917 · Data updated 2026-11-12
This study is looking at how a specific protein called sphingosine kinase 1 helps the body fight off a fungal infection that can be especially dangerous for people with weakened immune systems, like those undergoing certain treatments, to find better ways to treat this infection and its serious complications.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | State University New York Stony Brook NIH-funded |
| Lab location | 1 site (Stony Brook, United States) |
| Project start | February 1, 2025 |
| Project end | January 31, 2030 |
| Funding year | 2025 |
| Award (this year) | $749,594 |
| NIH project number | 1R01AI184929-01A1 |
| Project ID | NIH-11126917 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research include individuals with immunodeficiency, such as those living with HIV/AIDS or patients undergoing immunosuppressive therapies.
✕Less likely to help
Patients with strong immune systems or those not at risk for cryptococcal infections may not benefit from this research.
What this research studies
This research focuses on understanding the role of sphingosine kinase 1 (SK1) in controlling infections caused by the fungus Cryptococcus neoformans, particularly in individuals with weakened immune systems. Using a mouse model that simulates human granuloma, the study examines how the SK1 pathway influences the body's response to this fungal infection. The research aims to uncover mechanisms that lead to severe complications, such as meningo-encephalitis, when the infection spreads to the brain. Insights gained could inform treatment strategies for patients at risk of cryptococcosis, especially those undergoing therapies that affect immune function.
Why it matters
Potential benefit: If successful, this research could lead to improved treatment strategies for patients with weakened immune systems, reducing the risk of severe fungal infections.
How similar studies have gone: Previous studies have shown that targeting the SK1 pathway can influence fungal infections, indicating potential for success in this area of research.
Where this research is happening
-
State University New York Stony Brook
Stony Brook, United States Active
Researchers
- Principal investigator: Del Poeta, Maurizio — State University New York Stony Brook
- Study coordinator: Del Poeta, Maurizio
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.